Similar to our results, Lee et al. observed a weak decline in CD4+/CD25+/FoxP3+ Tregs in patients with oral squamous cell carcinoma compared to healthy controls [24], while a rise in the frequency of Tregs was found in patients with SCCHN treated with adjuvant RCT [5, 32]. Here, FOXP3 is linked to head and neck squamous cell carcinoma.